• Treffer 2 von 16
Zurück zur Trefferliste

Protocadherin Gamma C3 (PCDHGC3) is strongly expressed in glioblastoma and its high expression is associated with longer progression-free survival of patients

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-284433
  • Protocadherins (PCDHs) belong to the cadherin superfamily and represent the largest subgroup of calcium-dependent adhesion molecules. In the genome, most PCDHs are arranged in three clusters, α, β, and γ on chromosome 5q31. PCDHs are highly expressed in the central nervous system (CNS). Several PCDHs have tumor suppressor functions, but their individual role in primary brain tumors has not yet been elucidated. Here, we examined the mRNA expression of PCDHGC3, a member of the PCDHγ cluster, in non-cancerous brain tissue and in gliomas ofProtocadherins (PCDHs) belong to the cadherin superfamily and represent the largest subgroup of calcium-dependent adhesion molecules. In the genome, most PCDHs are arranged in three clusters, α, β, and γ on chromosome 5q31. PCDHs are highly expressed in the central nervous system (CNS). Several PCDHs have tumor suppressor functions, but their individual role in primary brain tumors has not yet been elucidated. Here, we examined the mRNA expression of PCDHGC3, a member of the PCDHγ cluster, in non-cancerous brain tissue and in gliomas of different World Health Organization (WHO) grades and correlated it with the clinical data of the patients. We generated a PCDHGC3 knockout U343 cell line and examined its growth rate and migration in a wound healing assay. We showed that PCDHGC3 mRNA and protein were significantly overexpressed in glioma tissue compared to a non-cancerous brain specimen. This could be confirmed in glioma cell lines. High PCDHGC3 mRNA expression correlated with longer progression-free survival (PFS) in glioma patients. PCDHGC3 knockout in U343 resulted in a slower growth rate but a significantly faster migration rate in the wound healing assay and decreased the expression of several genes involved in WNT signaling. PCDHGC3 expression should therefore be further investigated as a PFS-marker in gliomas. However, more studies are needed to elucidate the molecular mechanisms underlying the PCDHGC3 effects.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Jonas Feldheim, David Wend, Mara J. Lauer, Camelia M. Monoranu, Martin Glas, Christoph Kleinschnitz, Ralf-Ingo Ernestus, Barbara M. Braunger, Patrick MeybohmORCiD, Carsten Hagemann, Malgorzata Burek
URN:urn:nbn:de:bvb:20-opus-284433
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Graduate Schools / Graduate School of Life Sciences
Medizinische Fakultät / Neurochirurgische Klinik und Poliklinik
Medizinische Fakultät / Pathologisches Institut
Medizinische Fakultät / Institut für Anatomie und Zellbiologie
Medizinische Fakultät / Klinik und Poliklinik für Anästhesiologie (ab 2004)
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):International Journal of Molecular Sciences
ISSN:1422-0067
Erscheinungsjahr:2022
Band / Jahrgang:23
Heft / Ausgabe:15
Aufsatznummer:8101
Originalveröffentlichung / Quelle:International Journal of Molecular Sciences (2022) 23:15, 8101. doi:10.3390/ijms23158101
DOI:https://doi.org/10.3390/ijms23158101
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Freie Schlagwort(e):PCDHGC3; WNT signaling; astrocytoma; brain; expression; glioblastoma multiforme; glioma; mRNA; protein; recurrence; relapse
Datum der Freischaltung:19.04.2023
Datum der Erstveröffentlichung:22.07.2022
Open-Access-Publikationsfonds / Förderzeitraum 2022
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International